Jaguar Health Inc
Research Jaguar Health Inc (JAGX) on Bullrun: market cap USD 1.50M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJAGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.50M
- Financial periodQ2 2026
- RevenueUSD 1.23M
- Net income-USD 12.68M
- Free cash flow-USD 5.34M
- Gross margin15.8%
Valuation Snapshot
latest market cap is USD 1.50M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 11.51M | -USD 54.00K | -USD 23.73M | 67.2% | -22.97 | USD 968.00K | USD 43.61M | -USD 18.69M |
| FY2024 | USD 11.69M | -USD 39.25K | -USD 29.40M | 83.3% | -130.69 | USD 8.00M | USD 36.53M | USD 6.49M |
| FY2023 | USD 9.76M | -USD 41.90K | -USD 33.24M | 79.1% | -2678.17 | USD 6.47M | USD 37.09M | USD 4.90M |
| FY2022 | USD 11.96M | -USD 48.40K | -USD 33.18M | 83.1% | -36.18 | USD 5.47M | USD 34.84M | -USD 1.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 1.50M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.18M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.34M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.93M | n/a | n/a | n/a |
About Jaguar Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jaguar Health Inc's market cap?
Jaguar Health Inc's market capitalization is USD 1.50M.
What does Jaguar Health Inc do?
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.